Experts in immune-oncology therapies developing proprietary FHAB™ (Fully Human Albumin Binding) technology. (NASDAQ: $SONN)
Joined September 2017
- Tweets 179
- Following 3
- Followers 559
- Likes 17
151 Photos and videos
2 Dec 2025
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
bit.ly/48qxQq8
$SONN
1
1
5
902
2 Dec 2025
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
bit.ly/3M5j1C5
$SONN
2
3
14
2,147
18 Nov 2025
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
bit.ly/49pKB6D
$SONN #Oncology #SolidTumors
1
3
735
17 Oct 2025
#DidYouSee: We entered into a collaboration with Spanios to evaluate SON-1010 (IL-12-FHAB) using a patient-derived tumoroid platform to support an ongoing Phase 1 study in patients with sarcoma.
Learn more: bit.ly/3Wc1hqq
$SONN #Oncology #Sarcoma #SolidTumors
2
795
29 Sep 2025
Gynecologic Cancer Awareness Month may be ending, but our commitment doesn’t stop.
Find out how you can get involved and make a difference: bit.ly/3WVPayQ
$SONN #GynecologicCancer #CancerAwareness
1
650
25 Sep 2025
Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a fully modular technology that enables the design of single or bifunctional biologic compounds that target solid tumors by binding albumin, which in turn, binds to FcRn, GP60 and SPARC.
$SONN
1
3
995
22 Sep 2025
Our CEO, Raghu Rao, provides an update on SON-1010, highlighting progress in finding the optimal dose with atezolizumab, monitoring patient safety and responses and preparing to test a higher dose as the study advances toward Part 2.
$SONN #Oncology #SolidTumors
2
911
19 Sep 2025
Sonnet to Present at the MedInvest Biotech & Pharma Conference
bit.ly/4mprmwK
$SONN #Oncology #SolidTumors
1
1
644
16 Sep 2025
Stay informed on the latest news, clinical updates and company announcements from Sonnet.
Sign up for email alerts here: bit.ly/4cOlI3c
$SONN #Oncology #SolidTumors
3
542
12 Sep 2025
We recently participated in a #VirtualInvestor #WhatThisMeans segment, where CMO Dr. Richard Kenney discussed the expansion of the SB221 trial in platinum-resistant #OvarianCancer and our plans to evaluate higher doses ahead of Phase 2a next year.
vimeo.com/1108857330?share=c…
$SONN
692
5 Sep 2025
💜 September is #OvarianCancerAwarenessMonth — a time to unite, raise awareness and support those affected.
Learn how you can make an impact: bit.ly/3YALP7u
$SONN #Oncology #OvarianCancer #EndOvarianCancer
466
4 Sep 2025
This September, we’re shining a light on Gynecologic Cancer Awareness Month. Join us in supporting patients, spreading awareness and making a difference: bit.ly/3WVPayQ
$SONN #GynecologicCancer #CancerAwareness
406
21 Aug 2025
The Sonnet team combines unparalleled expertise in cytokine biology with extensive, proven success in drug discovery and development — driving innovation that transforms patient care.
Explore more about $SONN leadership here: bit.ly/3WAGFsM
#Oncology #SolidTumors
1
1
648
15 Aug 2025
Tumors often resist immunotherapy by creating an immune-suppressive tumor microenvironment. We're working to address this, with our technology designed to deliver immune-activating cytokines like IL-12 directly to the TME — enhancing half-life, safety, and therapeutic benefit.
1
435
12 Aug 2025
Stay informed — sign up for email alerts and never miss an update: bit.ly/4cOlI3c
$SONN #Oncology #SolidTumors
1
484
Sonnet Bio retweeted
11 Aug 2025
Sonnet participated in a What This Means segment, where CMO Dr. Richard Kenney discussed the expansion of its SB221 trial in platinum-resistant ovarian cancer and plans to evaluate higher doses ahead of Phase 2a next year.
Watch here: vimeo.com/1108857330?share=c…
$SONN @sonnetbio
1
1
775
11 Aug 2025
Sonnet Releases Virtual Investor "What This Means" Segment
bit.ly/3H8RLjX
$SONN #Oncology #SolidTumors
2
480
6 Aug 2025
#InCaseYouMissedIt: We recently announced an $888 million business combination to launch Sonnet BioTherapeutics’ HYPE Cryptocurrency Treasury Reserve Strategy.
Learn more about this here: bit.ly/4nHnlpb
$SONN #Oncology #SolidTumors
2
3
1,262
4 Aug 2025
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
bit.ly/45iQcro
$SONN #Oncology #SolidTumors
1
1
509
14 Jul 2025
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
bit.ly/4nHnlpb
$SONN
6
2
13
1,767